Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial

Abstract

Tapinarof cream 1% once daily demonstrated significant efficacy versus vehicle and was well tolerated in two 12-week, phase 3 pivotal trials in adults with mild to severe plaque psoriasis. Assess long-term, health-related quality of life (HRQoL) and patient satisfaction with tapinarof. Patients completing the 12-week trials were eligible for 40 weeks of open-label tapinarof based on Physician Global Assessment score in PSOARING 3, with a 4-week follow-up. Dermatology Life Quality Index (DLQI) was assessed at every visit; Patient Satisfaction Questionnaire© (PSQ) responses were assessed at Week 40 or early termination. 763 (91.6%) eligible patients enrolled; 78.5% completed the PSQ. DLQI scores improved and were maintained. By Week 40, 68.0% of patients had a DLQI of 0 or 1, indicating no impact of psoriasis on HRQoL. Most patients strongly agreed or agreed with all PSQ questions assessing confidence in tapinarof and satisfaction with efficacy (62.9-85.8%), application ease and cosmetic elegance (79.9-96.3%), and preference for tapinarof versus prior psoriasis therapies (55.3-81.7%). Open-label; no control; may not be generalizable to all forms of psoriasis. Continued and durable improvements in HRQoL, high rates of patient satisfaction, and positive perceptions of tapinarof cream were demonstrated.